NO321380B1 - Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter. - Google Patents

Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter. Download PDF

Info

Publication number: NO321380B1
Authority: NO; Norway
Prior art keywords: residue; heptapeptide; heptapeptide analogue; analogue according; unit
Prior art date: 1996-11-26

Application number

NO19992532A

Other languages

English (en)

Norwegian (no)

Other versions

NO992532L (no

NO992532D0 (no

Inventor

Anders Nilsson

Per Melin

Jerzy Trojnar

Carl-Johan Aurell

Pierre Riviere

Robert Haig

Original Assignee

Ferring Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-26

Filing date

1999-05-26

Publication date

2006-05-02

1999-05-26 Application filed by Ferring Bv filed Critical Ferring Bv

1999-05-26 Publication of NO992532L publication Critical patent/NO992532L/no

1999-05-26 Publication of NO992532D0 publication Critical patent/NO992532D0/no

2006-05-02 Publication of NO321380B1 publication Critical patent/NO321380B1/no

Links

230000000694 effects Effects 0.000 title claims description 22
238000000034 method Methods 0.000 title claims description 17
239000003336 oxytocin antagonist Substances 0.000 title claims description 13
229940121361 oxytocin antagonists Drugs 0.000 title claims description 13
239000003814 drug Substances 0.000 title claims description 10
229940079593 drug Drugs 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 6
150000001875 compounds Chemical class 0.000 claims description 38
239000000203 mixture Substances 0.000 claims description 28
-1 aliphatic α-amino acid Chemical class 0.000 claims description 17
235000008206 alpha-amino acids Nutrition 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 12
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 11
210000000754 myometrium Anatomy 0.000 claims description 9
QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
208000005171 Dysmenorrhea Diseases 0.000 claims description 7
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims description 6
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
210000004899 c-terminal region Anatomy 0.000 claims description 6
230000008602 contraction Effects 0.000 claims description 6
239000004474 valine Substances 0.000 claims description 6
AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 claims description 5
206010036600 Premature labour Diseases 0.000 claims description 5
150000001414 amino alcohols Chemical class 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
229960000310 isoleucine Drugs 0.000 claims description 5
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
230000004118 muscle contraction Effects 0.000 claims description 5
WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims description 4
208000006399 Premature Obstetric Labor Diseases 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 4
239000006172 buffering agent Substances 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
208000026440 premature labor Diseases 0.000 claims description 4
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical group OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 3
208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
230000002519 immonomodulatory effect Effects 0.000 claims description 3
201000001881 impotence Diseases 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
201000000980 schizophrenia Diseases 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
239000012279 sodium borohydride Substances 0.000 claims description 2
125000000266 alpha-aminoacyl group Chemical group 0.000 claims 6
229930182827 D-tryptophan Natural products 0.000 claims 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 3
206010061218 Inflammation Diseases 0.000 claims 2
230000005856 abnormality Effects 0.000 claims 2
230000003542 behavioural effect Effects 0.000 claims 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
239000002702 enteric coating Substances 0.000 claims 2
238000009505 enteric coating Methods 0.000 claims 2
206010020718 hyperplasia Diseases 0.000 claims 2
230000004054 inflammatory process Effects 0.000 claims 2
235000013336 milk Nutrition 0.000 claims 2
239000008267 milk Substances 0.000 claims 2
210000004080 milk Anatomy 0.000 claims 2
230000009826 neoplastic cell growth Effects 0.000 claims 2
YHZCTZGJKHNVQY-LURJTMIESA-N (2s)-2-(diethylazaniumyl)propanoate Chemical compound CCN(CC)[C@@H](C)C(O)=O YHZCTZGJKHNVQY-LURJTMIESA-N 0.000 claims 1
JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
230000000903 blocking effect Effects 0.000 claims 1
229910000085 borane Inorganic materials 0.000 claims 1
239000008187 granular material Substances 0.000 claims 1
229910052739 hydrogen Inorganic materials 0.000 claims 1
239000001257 hydrogen Substances 0.000 claims 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 description 23
239000000243 solution Substances 0.000 description 23
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 16
229960001723 oxytocin Drugs 0.000 description 16
101800000989 Oxytocin Proteins 0.000 description 15
102400000050 Oxytocin Human genes 0.000 description 15
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 15
239000000556 agonist Substances 0.000 description 13
239000003826 tablet Substances 0.000 description 11
239000005557 antagonist Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
229940024606 amino acid Drugs 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 7
230000004044 response Effects 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
229920005989 resin Polymers 0.000 description 5
239000011347 resin Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
208000033045 Premenstrual cramps Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
210000004291 uterus Anatomy 0.000 description 4
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
125000003941 D-tryptophan group Chemical group [H]C1=C([H])C([H])=C2C(C([C@@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
IHXHBYFWSOYYTR-CYBMUJFWSA-N (2r)-3-(1-formylindol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2C(C[C@@H](NC(=O)OC(C)(C)C)C(O)=O)=CN(C=O)C2=C1 IHXHBYFWSOYYTR-CYBMUJFWSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
239000013011 aqueous formulation Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
150000003138 primary alcohols Chemical class 0.000 description 2
239000000047 product Substances 0.000 description 2
238000011552 rat model Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
RMYPEYHEPIZYDJ-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-ethoxyphenyl)propanoate Chemical compound CCOC1=CC=C(C[C@H](N)C(O)=O)C=C1 RMYPEYHEPIZYDJ-JTQLQIEISA-N 0.000 description 1
HIJAUEZBPWTKIV-QFIPXVFZSA-N (2s)-3-cyclohexyl-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1CCCCC1 HIJAUEZBPWTKIV-QFIPXVFZSA-N 0.000 description 1
UMKHSOQAVNCWST-LURJTMIESA-N (2s)-5-amino-2-(ethylamino)pentanoic acid Chemical compound CCN[C@H](C(O)=O)CCCN UMKHSOQAVNCWST-LURJTMIESA-N 0.000 description 1
ZAQXSMCYFQJRCQ-UHFFFAOYSA-N 3-(1-adamantyl)-2-azaniumylpropanoate Chemical compound C1C(C2)CC3CC2CC1(CC(N)C(O)=O)C3 ZAQXSMCYFQJRCQ-UHFFFAOYSA-N 0.000 description 1
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
OXDZADMCOWPSOC-UHFFFAOYSA-N Argiprestocin Chemical compound N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 OXDZADMCOWPSOC-UHFFFAOYSA-N 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
101000986765 Homo sapiens Oxytocin receptor Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
241001582888 Lobus Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229940122828 Oxytocin receptor antagonist Drugs 0.000 description 1
102000004279 Oxytocin receptors Human genes 0.000 description 1
108090000876 Oxytocin receptors Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000012317 TBTU Substances 0.000 description 1
APQHKWPGGHMYKJ-UHFFFAOYSA-N Tributyltin oxide Chemical compound CCCC[Sn](CCCC)(CCCC)O[Sn](CCCC)(CCCC)CCCC APQHKWPGGHMYKJ-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
101800003024 Vasotocin Proteins 0.000 description 1
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
239000003160 antidiuretic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
150000003857 carboxamides Chemical group 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
230000012173 estrus Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000052321 human OXTR Human genes 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000005040 ion trap Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000006651 lactation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
150000002668 lysine derivatives Chemical class 0.000 description 1
150000002678 macrocyclic compounds Chemical class 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
230000019989 milk ejection Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
230000011273 social behavior Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
229940125712 tocolytic agent Drugs 0.000 description 1
239000003675 tocolytic agent Substances 0.000 description 1
230000003195 tocolytic effect Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Pregnancy & Childbirth (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

NO19992532A 1996-11-26 1999-05-26 Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter. NO321380B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9604341A SE9604341D0 (sv)	1996-11-26	1996-11-26	Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en)	1996-11-26	1997-11-21	Heptapeptide oxytocin analogues

Publications (3)

Publication Number	Publication Date
NO992532L NO992532L (no)	1999-05-26
NO992532D0 NO992532D0 (no)	1999-05-26
NO321380B1 true NO321380B1 (no)	2006-05-02

Family

ID=20404757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19992532A NO321380B1 (no)	1996-11-26	1999-05-26	Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter.

Country Status (35)

Country	Link
US (1)	US6143722A (et)
EP (1)	EP0938496B1 (et)
JP (1)	JP3405460B2 (et)
KR (1)	KR100463132B1 (et)
CN (1)	CN1129606C (et)
AR (1)	AR008531A1 (et)
AT (1)	ATE242264T1 (et)
AU (1)	AU713424B2 (et)
BR (1)	BR9713366B1 (et)
CA (1)	CA2272990C (et)
CZ (1)	CZ299532B6 (et)
DE (1)	DE69722651T2 (et)
DK (1)	DK0938496T3 (et)
EE (1)	EE03832B1 (et)
ES (1)	ES2203823T3 (et)
HK (1)	HK1022481A1 (et)
HR (1)	HRP970630B1 (et)
HU (1)	HU228568B1 (et)
IL (1)	IL129519A (et)
LT (1)	LT4650B (et)
LV (1)	LV12350B (et)
MY (1)	MY125555A (et)
NO (1)	NO321380B1 (et)
NZ (1)	NZ336445A (et)
PL (1)	PL189292B1 (et)
PT (1)	PT938496E (et)
RO (1)	RO120772B1 (et)
RU (1)	RU2180668C2 (et)
SE (1)	SE9604341D0 (et)
SI (1)	SI20026B (et)
SK (1)	SK283800B6 (et)
TR (1)	TR199901028T2 (et)
UA (1)	UA54459C2 (et)
WO (1)	WO1998023636A1 (et)
ZA (1)	ZA9710518B (et)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2181297C2 (ru)	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) *	2000-11-21	2002-11-05	Arthur Vanmoor	Method of treating menstrual pain by enhancing the effectiveness of the human immune system
JP4615221B2 (ja) *	2002-02-27	2011-01-19	フェリングベスローテンフェンノートシャップ	ヘプタペプチドオキシトシンアナログを製造するための中間体及び方法
EP1504268A2 (en) *	2002-05-02	2005-02-09	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en)	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
UA76639C2 (uk) *	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
EP1530967B1 (en) *	2003-11-13	2006-05-03	Ferring B.V.	Blister pack and solid dosage form comprising desmopressin
EP1555029A1 (en)	2004-01-19	2005-07-20	Ferring B.V.	Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) *	2005-02-03	2006-08-03	The Procter & Gamble Company	Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) *	2006-03-02	2006-11-14	Ferring Int Ct Sa	Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
JP5451613B2 (ja)	2007-08-06	2014-03-26	アラーガン、インコーポレイテッド	デスモプレシン薬物送達のための方法及びデバイス
BRPI0910345B1 (pt) *	2008-03-31	2021-08-17	Ferring B.V.	Compostos análogos de oxitocina, composição farmacêutica compreendendo os mesmos e uso dos ditos análogos
PT3225249T (pt)	2008-05-21	2019-01-17	Ferring Bv	Desmopressina orodispersível para aumentar o período inicial de sono não perturbado pela nocturia
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
TWI463990B (zh) *	2009-09-21	2014-12-11	Ferring Bv	催產素受體促進劑
MX2013000543A (es)	2010-07-15	2013-10-28	Oleg Iliich Epshtein	Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
JO3400B1 (ar) *	2010-09-30	2019-10-20	Ferring Bv	مركب صيدلاني من كاربيتوسين
JP6150726B2 (ja)	2011-03-09	2017-06-21	Jitsubo株式会社	新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物
CN102875650B (zh) *	2012-09-26	2014-06-11	深圳翰宇药业股份有限公司	巴卢西班的制备方法
US9365615B2 (en)	2013-09-09	2016-06-14	Jitsubo Co., Ltd.	Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3501533A1 (en)	2014-12-22	2019-06-26	Ferring B.V.	Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US9744239B2 (en)	2015-01-30	2017-08-29	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en)	2015-01-30	2018-04-10	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en)	2015-01-30	2017-08-29	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en)	2015-01-30	2018-03-27	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en)	2015-01-30	2017-09-05	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en)	2015-01-30	2017-06-27	Par Pharmaceutical, Inc.	Vasopressin formulations for use in treatment of hypotension
CA3001057A1 (en)	2015-10-06	2017-04-13	Ferring B.V.	New methods for making barusiban and its intermediates
PL3400217T3 (pl)	2016-01-04	2022-07-04	Merck Serono S.A.	L-walinian pochodnej hydroksypropylotiazolidynokarboksyamidu, jego sól i postać krystaliczna
SG11201900461UA (en)	2016-07-21	2019-02-27	ObsEva SA	Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2020340670A1 (en)	2019-09-03	2022-04-07	ObsEva S.A.	Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en)	2020-02-10	2023-03-30	ObsEva S.A.	Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2036973A1 (en) *	1990-02-27	1991-08-28	Mark G. Bock	Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) *	1990-07-09	1990-07-09	Ferring Ab	Derivat av baklobshormoner
SE501678C2 (sv) *	1993-07-13	1995-04-10	Ferring Bv	Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv)	1994-01-27	2004-05-18	Per-Ingvar Nilsson	Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv)	1994-03-18	1995-09-19	Anne Fjellstad Paulsen	Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv)	1995-01-25	1996-03-25	Valeo Engine Cooling Ab	Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

1996
- 1996-11-26 SE SE9604341A patent/SE9604341D0/xx unknown
1997
- 1997-11-21 HR HR970630A patent/HRP970630B1/xx not_active IP Right Cessation
- 1997-11-21 ES ES97946210T patent/ES2203823T3/es not_active Expired - Lifetime
- 1997-11-21 EE EEP199900210A patent/EE03832B1/et unknown
- 1997-11-21 ZA ZA9710518A patent/ZA9710518B/xx unknown
- 1997-11-21 US US09/308,912 patent/US6143722A/en not_active Expired - Lifetime
- 1997-11-21 DK DK97946210T patent/DK0938496T3/da active
- 1997-11-21 SI SI9720076A patent/SI20026B/sl unknown
- 1997-11-21 RO RO99-00593A patent/RO120772B1/ro unknown
- 1997-11-21 IL IL12951997A patent/IL129519A/en not_active IP Right Cessation
- 1997-11-21 CA CA002272990A patent/CA2272990C/en not_active Expired - Lifetime
- 1997-11-21 BR BRPI9713366-3A patent/BR9713366B1/pt not_active IP Right Cessation
- 1997-11-21 CZ CZ0183299A patent/CZ299532B6/cs not_active IP Right Cessation
- 1997-11-21 RU RU99113364/04A patent/RU2180668C2/ru active
- 1997-11-21 HU HU0000577A patent/HU228568B1/hu unknown
- 1997-11-21 KR KR10-1999-7004449A patent/KR100463132B1/ko not_active IP Right Cessation
- 1997-11-21 NZ NZ336445A patent/NZ336445A/en not_active IP Right Cessation
- 1997-11-21 DE DE69722651T patent/DE69722651T2/de not_active Expired - Lifetime
- 1997-11-21 WO PCT/SE1997/001968 patent/WO1998023636A1/en active IP Right Grant
- 1997-11-21 CN CN97180014A patent/CN1129606C/zh not_active Expired - Fee Related
- 1997-11-21 TR TR1999/01028T patent/TR199901028T2/xx unknown
- 1997-11-21 PT PT97946210T patent/PT938496E/pt unknown
- 1997-11-21 AT AT97946210T patent/ATE242264T1/de active
- 1997-11-21 SK SK704-99A patent/SK283800B6/sk not_active IP Right Cessation
- 1997-11-21 AU AU51429/98A patent/AU713424B2/en not_active Expired
- 1997-11-21 JP JP52460298A patent/JP3405460B2/ja not_active Expired - Lifetime
- 1997-11-21 PL PL97333876A patent/PL189292B1/pl unknown
- 1997-11-21 EP EP97946210A patent/EP0938496B1/en not_active Expired - Lifetime
- 1997-11-21 UA UA99042410A patent/UA54459C2/uk unknown
- 1997-11-25 MY MYPI97005691A patent/MY125555A/en unknown
- 1997-11-26 AR ARP970105543A patent/AR008531A1/es active IP Right Grant
1999
- 1999-04-30 LV LVP-99-77A patent/LV12350B/en unknown
- 1999-05-11 LT LT99-052A patent/LT4650B/lt not_active IP Right Cessation
- 1999-05-26 NO NO19992532A patent/NO321380B1/no not_active IP Right Cessation
2000
- 2000-03-07 HK HK00101422A patent/HK1022481A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1129606C (zh)	2003-12-03
EE9900210A (et)	1999-12-15
SK283800B6 (sk)	2004-02-03
WO1998023636A1 (en)	1998-06-04
TR199901028T2 (xx)	1999-07-21
JP2000507617A (ja)	2000-06-20
DE69722651D1 (en)	2003-07-10
HRP970630B1 (en)	2002-04-30
BR9713366B1 (pt)	2010-05-18
LV12350A (lv)	1999-09-20
EP0938496A1 (en)	1999-09-01
LV12350B (en)	1999-11-20
KR20000069045A (ko)	2000-11-25
AR008531A1 (es)	2000-01-19
US6143722A (en)	2000-11-07
IL129519A0 (en)	2000-02-29
NO992532L (no)	1999-05-26
AU5142998A (en)	1998-06-22
CZ299532B6 (cs)	2008-08-27
LT99052A (en)	2000-01-25
SK70499A3 (en)	2000-10-09
HUP0000577A2 (hu)	2000-11-28
RU2180668C2 (ru)	2002-03-20
SI20026B (sl)	2000-06-30
HK1022481A1 (en)	2000-08-11
ZA9710518B (en)	1998-06-10
BR9713366A (pt)	2000-01-25
ES2203823T3 (es)	2004-04-16
NO992532D0 (no)	1999-05-26
PT938496E (pt)	2003-10-31
SE9604341D0 (sv)	1996-11-26
AU713424B2 (en)	1999-12-02
CA2272990C (en)	2002-11-19
JP3405460B2 (ja)	2003-05-12
UA54459C2 (uk)	2003-03-17
NZ336445A (en)	2000-06-23
LT4650B (lt)	2000-04-25
RO120772B1 (ro)	2006-07-28
ATE242264T1 (de)	2003-06-15
EP0938496B1 (en)	2003-06-04
SI20026A (sl)	2000-02-29
HUP0000577A3 (en)	2001-02-28
DK0938496T3 (da)	2003-10-06
HU228568B1 (en)	2013-04-29
CZ183299A3 (cs)	2000-05-17
CN1238781A (zh)	1999-12-15
CA2272990A1 (en)	1998-06-04
DE69722651T2 (de)	2004-04-08
HRP970630A2 (en)	1998-10-31
PL189292B1 (pl)	2005-07-29
KR100463132B1 (ko)	2004-12-23
MY125555A (en)	2006-08-30
EE03832B1 (et)	2002-08-15
IL129519A (en)	2004-09-27

Publication	Publication Date	Title
NO321380B1 (no)	2006-05-02	Heptapeptid analog med oksytocinantagonistaktivitet, fremgangsmate ved fremstilling derav samt anvendelse derav til fremstilling av medikamenter.
FI92326C (fi)	1994-10-25	LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
US5068222A (en)	1991-11-26	Bombesin antagonists with deletion of net-residue at the c-terminus
NO301015B1 (no)	1997-09-01	Dekapeptid med antiovulatorisk aktivitet
Rivier et al.	1995	Gonadotropin-releasing hormone antagonists: novel members of the azaline B family
NO854645L (no)	1986-05-22	Fremgangsmaate for fremstilling av basiske cykliske peptider.
CA2405704C (en)	2010-11-16	Bombesin analogs for treatment of cancer
PT98498A (pt)	1992-05-29	Processo para a preparacao de polipeptidos e de composicoes farmaceuticas que os contem
US6989371B1 (en)	2006-01-24	Bombesin analogs for treatment of cancer
AU8225191A (en)	1992-02-04	Derivatives of pituitary posterior lobe hormones
TW386086B (en)	2000-04-01	Heptapeptide oxytocin analogues
US4658015A (en)	1987-04-14	Polypeptide intermediates
WO1995002609A1 (en)	1995-01-26	Peptides exhibiting oxytocin antagonistic activity

Legal Events

Date	Code	Title	Description
2017-12-11	MK1K	Patent expired